Table Graph
   

anti-inflammatory therapies - versus standard of care - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.98 [0.89, 1.07]< 127%7 studies (6/1)68.7 %moderateserious moderatecrucial-
deaths 0.77 [0.63, 0.95]< 175%10 studies (7/3)99.3 %moderatecritical moderatecrucial-
deaths (time to event analysis only) 0.38 [0.07, 2.16]< 193%2 studies (1/1)86.0 %lownot evaluable highcrucial-
clinical deterioration 0.27 [0.09, 0.83]< 10%3 studies (3/-)98.9 %some concernnot evaluable moderateimportant-
clinical improvement 10.27 [1.17, 90.18]> 10%1 study (1/-)98.2 %NAnot evaluable important-
clinical improvement (14-day) 10.27 [1.17, 90.18]> 10%1 study (1/-)98.2 %NAnot evaluable important-
clinical improvement (28-day) 3.52 [1.28, 9.72]> 10%2 studies (1/1)99.2 %NAnot evaluable important-
clinical improvement (7-day) 6.72 [1.50, 30.07]> 10%1 study (1/-)99.4 %NAnot evaluable important-
death or ventilation 0.94 [0.78, 1.15]< 170%2 studies (2/-)71.9 %some concernnot evaluable moderateimportant-
hospital discharge 2.06 [0.77, 5.49]> 187%3 studies (1/2)92.5 %lownot evaluable highimportant-
mechanical ventilation 0.79 [0.57, 1.08]< 162%6 studies (5/1)93.2 %moderateserious moderateimportant-
radiologic improvement (14-day) 2.87 [1.56, 5.28]> 10%1 study (1/-)100.0 %NAnot evaluable important-
ICU admission 0.92 [0.54, 1.58]< 10%2 studies (2/-)61.6 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 0.24 [0.01, 5.41]< 10%1 study (1/-)81.3 %NAnot evaluable important-
adverse events 1.75 [0.75, 4.07]< 10%2 studies (2/-)9.7 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons